Primary adhesive capsulitis of the shoulder is characterized by insidious pain leading to progressive loss of active and passive glenohumeral joint motion. The prevalence in the population is slightly more than 2%, and approximately 70% of patients are women, especially those aged 40-65 years. Other risk factors for the disease include diabetes, thyroid disease, and autoimmune diseases. It is a self-limiting disease that lasts 12-24 months and consists of 4 stages. 10-20% of cases report persistent shoulder stiffness more than 2 years after onset. Neviaser arthroscopic primary adhesive capsulitis is divided into four stages: Stage I or pre-adhesion presents with vasodilated synovitis on the entire inner surface of the capsule, most notably in the rotational interval. Stage II presents as a densely vascularized proliferative synovitis. Stage III is characterized by thinning of the residual synovial layer and local patchy thickening without vascular proliferation. There are few synovial adhesions in the inferior joint capsule crypt. Stage IV patients are rarely treated surgically and the microscopic manifestations are not mentioned.